Endothelial cells and endothelial cell precursors encoding a therapeutic gene have induced antitumor responses in preclinical models. Culture of peripheral blood provides a rich supply of autologous, highly proliferative endothelial cells, also referred to as blood outgrowth endothelial cells (BOECs). The aim of this study was to evaluate a novel antiangiogenic strategy using BOECs expressing fms-like tyrosine kinase-1 (sFlt1) and/or angiostatin-endostatin (AE) fusion protein. Conditioned medium from BOECs expressing sFlt1 or AE suppressed in vitro growth of pulmonary vein endothelial cells by 70% compared with conditioned medium from non-transduced BOEC controls. Reverse transcriptase-PCR analysis indicated that systemically administered BOECs proliferated in tumor tissue relative to other organs in C3(1)SV40 TAG transgenic (C3TAG) mice with spontaneous mammary tumors. Tumor volume was reduced by half in C3TAG mice and in mice bearing established lung or pancreatic tumors in response to the treatment with sFlt1-BOECs, AE-BOECs or their combination. Studies of tumor vascular density confirmed that angiogenic inhibition contributed to slowed tumor growth. In an orthotopic model of glioma, the median survival of mice treated with sFlt1-BOECs was double that of mice receiving no BOEC treatment (P ¼ 0.0130). These results indicate that further research is warranted to develop BOECs for clinical application.
Introduction
Neovascularization is essential for tumor growth and metastasis. 1 Recent studies suggest that circulating endothelial progenitor cells travel through the circulation to sites of ongoing neovascularization and, once there or in circulation, differentiate into mature endothelial cells which then assist in new blood vessel formation in a process consistent with postnatal vasculogenesis. 2 Ex vivo cultures of human peripheral blood mononuclear cells can be used to create a population of blood outgrowth endothelial cells (BOECs). BOECs are not endothelial progenitor cells (EPCs), as they are mature differentiated endothelial cells that are the progeny of a circulating, marrow-derived, transplantable, true endothelial progenitor cells. 3 As a cellular vehicle for gene delivery, autologous BOECs have several advantages over other cell types, including low immunogenicity, ease of collection from the peripheral blood, ease of expansion, stability in cell culture and ease of genetic manipulation. Indeed, a 10 18 -fold expansion of BOECs can be achieved from only 50-100 ml of blood. 3 Moreover, these expanded BOECs maintain their phenotype and are amenable to genetic engineering as we and others have demonstrated earlier. 4 Previous work has shown that BOECs migrate through the circulatory system into the vascular bed of tumors in mice; however, the distribution of BOECs in tumor tissue and other organs was determined for only 3 days after BOEC infusion. 5 BOECs engineered to express endostatin are capable of secreting endostatin in the tumor microenvironment in vivo on a continuous basis, resulting in decreased tumor vascularization and tumor volume in mice bearing subcutaneously established Lewis lung tumors. 5 On the basis of these encouraging results, the next step to developing this technology was to assess the antitumor activity of antiangiogenic gene therapy with different gene products and in different tumor models, including ones thought to better represent human disease, such as spontaneous tumor models. In this study, a novel strategy was pursued using BOECs transduced using a retroviral vector to express the potent angiogenic inhibitors, soluble fms-like tyrosine kinase-1 (sFlt1) or angiostatin-endostatin (AE) fusion protein. 6 These angiogenic inhibitors antagonize distinct signaling networks involved in neovascularization, and therefore their combination could result in enhanced antitumor activity. BOECs expressing sFlt1 or AE were systemically delivered to mice, alone and in combination, to evaluate their effects on primary tumor growth, metastasis and survival in subcutaneous models of lung and pancreatic cancer, a model of spontaneous breast cancer metastasis, and an induced orthotopic model of glioma, respectively. In addition, the in vivo fate of systemically infused BOECs was monitored over a longer period of time compared with the previous studies.
Materials and methods

Cell culture
Murine Lewis lung carcinoma cells and human pancreatic cancer S2VP10 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U ml À1 of penicillin and 100 mg ml À1 of streptomycin. Murine pulmonary vein endothelial cells (PVECs) and murine BOECs were grown and maintained using EGM-2 Bullet Kit medium (Clonetics, San Diego, CA) supplemented with 10% fetal bovine serum and 0.15 g 00l À1 dibutyryl cyclicadenosine monophosphate. 7 Human umbilical vein endothelial cells (HUVECs) and human BOECs were grown and propagated in EGM-2 Bullet Kit medium supplemented with 10% fetal bovine serum.
Construction of retroviral vector
Four retroviral vectors were constructed for the purposes of transfecting BOECs with the AE fusion protein, murine sFlt1, human sFlt1 (hsFlt) and DsRed. The internal ribosomal entry site DsRed cassette, consisting of 1959 base pairs, was cut from the pIRES-DsRedExpress vector (Clontech Laboratories, Mountain View, CA) with XhoI and NotI and cloned into the retroviral expression vector, PLNCX2. This vector was named PLNCX2-DsRed. Subsequently, a 2012 base pairs fragment expressing the AE fusion gene 6 and a 1012 base pairs DNA fragment containing sFlt1 were cloned upstream of internal ribosomal entry site in the PLNCX2-DsRed vector ( Figure 1 Plasmid DNA encoding PLNCX2-DsRed, PLNCX2-AE, PLNCX2-hsFlt1 (containing hsFlt) and PLNCX2-msFlt (containing mouse sFlt1 (msFlt1)) vectors ( Figure 1) were transfected into the virus-producing cell line, RetroPack PT67 (Clontech Laboratories), using Fugene6 according to the manufacturer's instructions (Roche Molecular Biochem, Indianapolis, IN). The stable cell line containing each of the four plasmids was then established by Neomycin selection for 3 to 4 weeks. Conditioned medium from PT67/DsRed was collected 48 h later and filtered through a 0.45 mm cellulose acetate filter and stored at À80 1C. Similarly, virus containing AE, hsFlt1 and msFlt1 was collected from the supernatant of PT67/AE, PT67/hsFlt1 and PT67/msFlt1, respectively.
Generation of stable transduced cell lines
BOECs at 60-70% confluence were transduced with each of the four vectors, respectively, by exposing cells to conditioned medium containing viral particles supplemented with 8 mg ml À1 of polybrene and 8 mg ml Blood outgrowth endothelial cell-based cancer gene therapy V Bodempudi et al medium. This step was repeated four to five times to increase the number of infected BOECs. Cells that were positive for the specific gene transfer were sorted using fluorescence-activated cell sorting. Sorted cells were maintained with complete medium containing 0.15 mg ml À1 of G418 for selection of pure populations of transgene-positive cells.
Detection of transgene products and BOEC phenotype Levels of endostatin, hsFlt-1 and msFlt in BOEC culture supernatant and mouse plasma fractions were determined by using murine endostatin and Flt1 enzyme-linked immunosorbent assay (ELISA) kits (Chemicon International, Temecula, CA and R&D Systems, Minneapolis, MN, respectively). ELISA was carried out according to the manufacturer's instruction. Cells only transfected with DsRed served as a control for the ELISA.
Endothelial phenotype for each of the transfected BOECs was determined by morphology and expression of the endothelial markers flt-1, VE-cadherin and CD31. Expression of markers for monocytes (CD14) and leukocyte common antigen (CD45) were used as negative controls.
Cell proliferation assay
Conditioned medium was collected from flasks containing AE-BOECs, hsFlt-BOECs, msFlt-BOECs or DsredBOECs. Medium was filtered through a 0.45 mm filter unit, and aliquots were stored at À70 1C for further use. PVECs were seeded in 96-well plates precoated with 1% gelatin at a density of 3 Â 10 3 cells per well. Thawed conditioned medium supplemented with 0.15 g l À1 dibutyryl cyclic adenosine monophosphate and 50 ng ml À1 of basic fibroblast growth factor was added to the six wells per group. Positive control wells had PVECs with basal medium supplemented with dibutyryl cyclic adenosine monophosphate and fibroblast growth factor. PVEC proliferation was determined at 24, 48 and 72 h by tetrazolium salt WST-1 proliferation assay (Roche Molecular Biochem) according to the manufacturer's protocol. For hsFlt-BOECs, the proliferation assay was performed on both HUVECs and PVECs. Tumor volume and metastases in mice with spontaneous mammary carcinoma C3(1)SV40 TAG transgenic (C3TAG) mice. Female transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen (C3TAG) fusion gene develop highly invasive breast tumors and show the evolutionary spectrum of human infiltrating ductal carcinoma. 8 These mice develop ductal epithelial atypia at 8 weeks, progression to intraepithelial neoplasia at 12 weeks (resembling human ductal carcinoma in situ), and invasive carcinoma and grossly palpable tumors at 16 weeks. By 6 months of age, all of the female mice die because of universal development of multifocal mammary adenocarcinomas. Breeder pairs of C3TAG mice on FVB/N strain were obtained from National Cancer Institute, Frederick, MD, USA. Mice were bred and genotyped as described. 8 A total of 20 female mice were divided into two groups receiving murine BOECs (derived from FVB/N background mice to avoid immunologic rejection as would be the case for human BOECs) either transduced with DsRed (n ¼ 15) or msFlt1 (n ¼ 5). Mice (10-to 11-week) were injected through the tail vein with a dose of 500 000 DsRed-mBOECs or msFlt1-mBOECs every other day for a total of three injections. All of the injected mBOECs were collected from male mice. Mice receiving DsRedmBOEC injections were euthanized on days 0, 9 and 15 (n ¼ 5 per time point) for analysis of tumors size and metastases. Mice injected with msFlt1-mBOECs were killed on day 9 (n ¼ 5). This experiment was performed twice independently, with analyses performed on 15 mice injected with DsRed-mBOECs and 5 mice injected with msFlt1-mBOECs. Tumor volumes were calculated as length Â width 2 /2. After tumor measurements, tumors and other organs from the 30 mice receiving DsRedmBOECs were analyzed for the presence of Y chromosome-specific DNA sequences (SRY gene) by quantitative reverse transcriptase-PCR as described above.
Tumor size in mice with subcutaneously established lung and pancreatic carcinomas Eighty NOD/SCID mice were purchased from Jackson Laboratory (Bar Harbor, ME 04609). Mice (6-week old) were injected in the tail vein with antiasialo GM1 antibody (Wako, Richmond, VA), in order to eliminate natural killer cell activity in this mouse strain, 9 which Quantification of tumor blood vessel density CD31-stained tumor sections were quantified to assess microvessel density. Tumor microvessels were counted in sections after staining with antibodies specific to CD31 according to methods described previously. 5 Briefly, areas containing the highest number of capillaries were identified by scanning the tumor sections at low power ( Â 40). After the areas of high vascular density were identified, the number of microvessels was assessed by counting microvessels in random 0.0321-mm 2 fields taken of each section at Â 200 magnification. On the basis of the criteria described by Weidner et al. 10 observation of a vessel lumen was not required.
Survival of mice with oncogene-induced glioma
The method employed to induce brain tumors was described previously. 11 Briefly, gliomas were induced in 1-day-old C57BL/6 mice in the right ventricle via cotransfection of plasmid DNA/polyethylenimine complexes encoding SV40-LgT, hyperactive human NRAS, and firefly luciferase with the Sleeping Beauty transposase gene. The injection into the right cerebral ventricle was performed with a 30-gauge hypodermic needle (12.5 bevel, Hamilton Company, Reno, NV) attached to a micropump (Stoelting, Wood Lake, IL). Within 48 h, mice were imaged to confirm luciferase expression. At 3 weeks after implantation, brain tumors in mice were verified with the IVIS 100 in vivo bioimaging system (Alameda, CA). A total of 27 tumor-bearing mice were divided into three groups of mice receiving no treatment (n ¼ 10), wild-type murine BOECs (n ¼ 7) or murine BOECs encoding hsFlt1 (n ¼ 10). BOECs (500 000 cells) were injected through the tail vein every other day for a total of three injections. In this experiment, murine BOECs cultured from C57BL/6 mice were used to avoid rejection as would occur if human BOECs were used in this immunocompetent mouse model. Animals were killed at the moribund state, when they could not reach food and water.
Statistical methods
Analysis of variance and t-tests were performed as appropriate to test for differences between control and experimental groups. Means±standard errors are reported unless otherwise noted. Comparison of the number of metastatic tumors between treatment groups was carried out using Poisson regression. The natural log transformation was used for analyses involving tumor volumes, and the Cox method was used to calculate means and confidence intervals (CIs) on the original scale. 12 
Kaplan-Meier survival curves and median survival was determined for each of the treatment groups. 13 Survival was compared between treatment groups using the log rank test. A P-value of less than 0.05 was considered statistically significant. All analyses were carried out in SAS Version 9.2 (SAS Institute, Cary, NC).
Results
Phenotype and transgene expression of engineered BOECs Human and mouse BOECs were stably transduced with either the AE fusion protein, msFlt1, hsFlt1, or DsRed. Engineered BOECs retained the morphology and surface markers of endothelial cells (data not shown). Transgene expression of endostatin (in BOECs with the AE fusion gene), msFlt1 and hsFlt1 (in BOECs transduced with the murine or hsFlt gene) was verified with the respective ELISA test. Supernatant collected in quinticates (n ¼ 5) from 48-h cultures of BOECs (1 Â 10 6 cells) encoding AE, msFlt1 or hsFlt1 contained, respectively, 504±19 ng ml À1 of endostatin, 399±3 ng ml À1 of msFlt1 and 406± 9 ng ml À1 of hsFlt1. By comparison, only a negligible fraction of these proteins was detected in supernatant collected from DsRed-BOECs and mouse serum.
Endothelial cell proliferation in cultures containing BOEC supernatant
To evaluate the biological function of endostatin and Flt-1, a proliferation assay was performed by growing murine PVECs in supernatant collected from AE-BOECs and msFlt1-BOECs. Compared with control DsRedBOECs, a 70% decrease in the growth of PVECs was observed after 48 h of culture (Figure 2 ; P-value for difference o0.0001). HsFlt-BOECs were capable of inhibiting both PVECs and human umbilical vein endothelial cells at comparable levels as that seen for AE-BOECs and msFlt1-BOECs (data not shown). Supernatant from murine BOECs encoding AE did not inhibit human umbilical vein endothelial cell proliferation (data not shown).
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In vivo distribution of BOECs in the tumor, liver, spleen and kidney Male mouse DsRed-mBOECs were injected into the tail vein of 30 female C3TAG mice with spontaneous mammary tumors. To assess the in vivo distribution of mBOECs, tumors and organs were harvested on days 0, 9 and 15 after BOEC injection for quantitative reverse transcriptase-PCR analysis of Y chromosome-specific DNA sequences (Figure 3) . Within the first 3 h of injection, BOECs were identified in the liver, kidney, spleen and tumor, with the majority of cells trapped in the lungs. By day 9, however, the number of cells in lung tissue was significantly lower than that seen in the tumor (P ¼ 0.0001). By day 15, the number of BOECs in tumor tissue increased significantly compared with day 9 (Po0.0001), whereas the number of BOECs decreased in the liver (P ¼ 0.0042). The number of BOECs decreased in the lungs, and kidneys, and remained stable in spleen from 3 h until day 15, though this observation did not reach statistical significance (P ¼ 0.2152, 0.1007 and 0.5529, respectively).
Metastasis in a spontaneous mammary tumor model
Female C3TAG mice with spontaneous mammary tumors were killed on days 0, 9 and 15 after completing a series of injections with DsRed-mBOECs or msFlt1-mBOECs. In mice injected with DsRed-mBOECs, tumor size increased gradually from day 0 to 15 (data not shown). In contrast, mice receiving msFlt1-mBOECs had smaller primary and fewer metastatic tumors, which were seen mostly in lung, on day 9 compared with control mice receiving DsRed-mBOECs (P ¼ 0.0613; Figures 4a and b) . Further, the average tumor volume for all mice receiving msFlt1-mBOECs was reduced by 65% by day 9 compared with mice receiving DsRed-mBOECs (msFlt-mBOECs: 35.4 mm 
Subcutaneous growth and vascularization of lung and pancreatic tumors
Mice were implanted with subcutaneous Lewis lung carcinoma cells. On days 4, 6 and 8 after tumor implantation, mice were injected with either DsRedhBOECs, AE-hBOECs, hsFlt1-hBOECs or AE þ hsFlt1-hBOECs (500 000 cells per injection). Immediately after the last hBOEC injection, the average tumor volume of Lewis lung tumors was 86.4 ± 3.5 mm 3 . Tumor growth in mice receiving combination AE þ hsFlt1-hBOECs was significantly slower than all other groups (Pp0.001; Figure 5a ). The average tumor volume in mice treated with control DsRed-hBOECs or AE þ msFlt1-hBOECs on day 13 was 978±60 mm 3 and 509±105 mm 3 , respectively. Neither treatment with AE-hBOECs alone nor hsFlt1-hBOECs alone resulted in significantly different tumor growth compared with controls (P ¼ 0.5394 and P ¼ 0.2269, respectively). In addition, vascular density in Lewis lung tumors was lower in mice injected with BOECs encoding msFlt1 or AE þ msFlt1 compared with controls (P ¼ 0.0608 and P ¼ 0.0287, respectively; Figures 5b and c).
Mice were also implanted with subcutaneous S2VP10 pancreatic cancer cells following the same procedure as described above (Figure 5d ). In this experiment, tumor growth was slower in all treatment groups compared with controls (P-values for AE, hsFLT1 and AE þ hsFLt1 were 0.0136, 0.0758 and 0.0655, respectively).
In vivo transgene expression of endostatin
To confirm the presence and sustainable production of transgene products, serum levels of murine endostatin were measured in mice implanted with Lewis lung carcinoma cells using an ELISA assay. Serum samples were collected at the end of the experiment described Figure 2 Inhibition of endothelial cell proliferation in vitro. A proliferation assay was performed on PVECs exposed to conditioned medium from transduced BOECs expressing AE, msFlt1 or DsRed or a medium from a mixed BOEC culture (AE þ msFlt1). Results are relative to PVECs cultured with basal medium supplemented with cyclic adenosine monophosphate and fibroblast growth factor. Data points represent the means±s.e. of six wells from one experiment.
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À1
) and 324 ng ml
(range: 260-342 ng ml À1 ), respectively. These endostatin levels were both significantly higher than the levels in mice injected with DsRed-hBOECs (152 ng ml
; range: 96-190 ng ml
; P ¼ 0.01 and P ¼ 0.03, respectively).
Survival of mice with oncogene-induced brain tumor
Brain tumors were induced by injecting SV40-LgT and NRAS transposons into the right ventricle of 1-day-old C57BL/6 mice as detailed in the methods. Overall survival was calculated from date of injection to date of death or was censored at last date of follow-up for mice still alive at the end of the experiment. Median survival was 102.5 days (95% CI: 48-108 days) for mice treated with hsFlt1-mBOECs (n ¼ 10), 66 days (95% CI: 41-80 days) for control mice receiving no treatment (n ¼ 10) and 51 days (95% CI: 36-93 days) for the mice treated with wild-type mBOECs (n ¼ 7) (Figure 6 ). Survival differed significantly when testing all three groups (P ¼ 0.0453). Survival was significantly better in mice treated with hsFlt-1-mBOECs compared with mice receiving no treatment (P ¼ 0.0130) and was borderline significantly better in mice treated with hsFlt-1-mBOECs compared with mice treated with wild-type BOECs (P ¼ 0.0871).
Discussion
This study demonstrates that BOEC infusions can be effectively used for the local delivery of angiogenic inhibitors to primary tumor and metastatic foci in a wide variety of solid tumors. Wei et al.
14 have reported that BOECs are selectively attracted to different primary tumors or metastases in particular organs. One explanation for this preferential attraction is that tumors and inflammatory cells residing within tumors secrete different levels of angiogenic growth factors, with vascular endothelial growth factor possibly being the primary chemoattractant for BOEC homing, though other factors may be involved such as placental growth factor and basic fibroblast growth factor. 15, 16 However, little is known about the mechanism by which circulating endothelial cells 17, 18 migrate to ischemic or cancerous tissue, with even less being known about the mechanism(s) attracting BOECs to pathologic tissue.
In this study, we observed tumor responses to BOECmediated angiogenic inhibition that are consistent with what is known about the pathophysiology of these tumors. BOECs expressing sFlt1 had a profound effect on the survival of mice with gliomas, which are abundantly vascularized tumors dependent on the vascular endothelial growth factor pathway. 19 In our pancreatic cancer model, single-agent treatment with BOECs expressing AE or sFlt inhibited tumor growth, Blood outgrowth endothelial cell-based cancer gene therapy V Bodempudi et al but their combination did not result in an additive effect, possibly because vascular endothelial growth factor inhibition is sufficient to achieve a maximal effect on angiogenic inhibition. Thus, addition of AE would not be expected to further improve the efficacy of this antiangiogenic strategy. However, the treatment of Lewis lung carcinoma tumors with BOECs expressing AE and BOECs expressing sFlt did result in improved inhibition compared with single-agent treatment. In this tumor model, angiogenic growth may be dependent on different growth factors; thus, the use of only one type of angiogenic inhibitor would be insufficient to impede tumor vascularization. We hypothesize that these differences among tumor types are likely because of different levels of dependency on the vascular endothelial growth factor pathway. When evaluating the clinical implications of an antiangiogenic BOEC, it is important to understand the impact of the transgene product on BOEC proliferation. Although non-transduced BOECs grow at a very fast pace in culture, their proliferation in vitro is negatively impacted by both the AE and sFlt1 proteins in suboptimal culture conditions. The addition of endothelial growth factors and serum to the culture medium overrides the inhibitory effect of the transgene product. Thus, sFlt, AE and DsRed BOECs are capable of growing in culture, albeit at a somewhat slower pace, and providing an ample supply of cells for gene transfer. Blood outgrowth endothelial cell-based cancer gene therapy V Bodempudi et al Although genetically modified BOECs can proliferate in vitro, it is still unknown how well they will proliferate in vivo in the hypoxic condition of growing tumor. Future studies will closely evaluate the effect of antiangiogenic transgenes on BOEC proliferation in vivo.
A suicide gene strategy has also been developed using transfused BOECs armed with a cytosine deaminase/ uracil phosphoriosyltransferase fusion gene. 14, 20 Our previous work has shown that BOECs integrate into tumor vessels at very low levels (5 BOECs/100 000 tumor cells). 5 As a result, long-term cell survival is an important aspect to consider when designing BOEC-mediated therapies. Unlike a suicide gene strategy, an antiangiogenic strategy allows for the constant production of angiogenic inhibitors by BOECs. In this study, sustainable levels of endostatin were detected in the serum of animals 24 days after the last BOEC infusion. These data are consistent with our in vitro data. Transgene expression was maintained for as long as it was tested (several months) in culture and over several cell passages and freezing/rethawing cycles. Thus, an antiangiogenic strategy is capable of delivering a continuous therapeutic effect. In addition, an antiangiogenic strategy is less dependent on the degree of endothelial cell integration into the tumor vasculature.
Another important question that remains unanswered is whether non-transduced BOECs accumulate, migrate, preferentially survive or proliferate in the tumor vasculature in vivo. We and others have previously reported that intravenously infused BOECs are initially found in the lung, liver, spleen and tumor but at later time points preferentially survive in the tumor vasculature and augment vessel growth through incorporation into the vessel endothelium. 5, 14, 21 A shortcoming of previous studies is that the distribution of BOECs was only tracked for short periods of time. This study tracked the number of BOECs in tumor tissue and other organs for 15 days after BOEC infusion. A large number of BOECs lodged in the pulmonary vasculature during their initial passage through the vascular network at 3 h. Although the number of BOECs in other organs remained relatively stable at days 9 and 15, the number of BOECs in tumor tissue increased from day 9 to day 15. If migration or accumulation were responsible for an increase in BOECs in tumor tissue, then one would expect the number of BOECs in other organs to decrease correspondingly. Because this was not observed, it is reasonable to tentatively conclude that BOECs are capable of surviving and proliferating in the tumor microenvironment. Additional preclinical studies of genetically modified BOECs will need to provide mechanistic evidence of BOEC proliferation in tumor tissue, quantify the degree of proliferation, and determine organ selectivity before this method of gene therapy delivery can be applied in the clinic.
The safety of using BOEC-mediated gene therapy is also an important concern with respect to both the BOEC itself and the biological effects of the transgene product. In our glioma model, even though the median survival of mice treated with BOECs encoding human Flt1 was 102.5 days, the median survival of mice treated with wild-type BOECs was 51 days compared with 66 days for mice receiving no treatment (P ¼ 0.6499). This finding may raise the concern that BOECs might promote tumor angiogenesis and facilitate tumor growth or spread, thus negatively affecting survival. Clinical applications may have to use rigorous techniques for producing pure populations of therapeutic BOECs that are not contaminated with wild-type BOECs. By using antibiotic selection, we have been able to prevent contamination with unmodified BOECs and establish pure populations of BOECs expressing antiangiogenic transgenes. Animals infused with pure populations of therapeutic BOECs have not exhibited any negative side effects on weight or behavior in our studies. Although additional safety evaluations will need to be performed in larger animals, our findings support the continued development of BOECs as a cellular vehicle for therapeutic gene transfer in an autologous setting.
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